Raltegravir potassium

• CAT Number: I008974
• CAS Number: 871038-72-1
• Molecular Formula: C20H20FKN6O5
• Molecular Weight: 482.5137
• Purity: ≥95%
• Target: HIV INTEGRASE
• Solubility: Soluble in DMSO.
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• IUPAC Name: potassium;4-[(4-fluorophenyl)methylcarbamoyl]-1-methyl-2-[2-[(5-methyl-1,3,4-oxadiazole-2-carbonyl)amino]propan-2-yl]-6-oxopyrimidin-5-olate
• InChI: InChI=1S/C20H21FN6O5.K/c1-10-25-26-17(32-10)16(30)24-20(2,3)19-23-13(14(28)18(31)27(19)4)15(29)22-9-11-5-7-12(21)8-6-11;/h5-8,28H,9H2,1-4H3,(H,22,29)(H,24,30);/q;+1/p-1
• InChIKey: IFUKBHBISRAZTF-UHFFFAOYSA-M
• SMILES: CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)[O-])C(=O)NCC3=CC=C(C=C3)F.[K+]

Raltegravir potassium (CAT: I008974) is an antiretroviral medication used for the treatment of HIV-1 infection. It belongs to the class of integrase strand transfer inhibitors (INSTIs) and works by inhibiting the integrase enzyme, which is responsible for inserting the viral DNA into the host cell’s DNA. By blocking this process, raltegravir prevents the replication of the HIV virus and helps reduce viral load in the body. Raltegravir potassium has shown efficacy in both treatment-naive and treatment-experienced HIV patients and is often included as part of combination antiretroviral therapy regimens.

Reference

1. Indian J Pharm Sci. 2014 Nov-Dec;76(6):557-9.

Spectrophotometric estimation of raltegravir potassium in tablets.

Kore PP(1), Gamepatil MM(1), Nimje HM(1), Baheti KG(1).

Author information:
(1)Department of Pharmaceutical Chemistry, Charak College of Pharmacy and
Research, Wagholi, Pune-412 207, India.

Ultra violet spectrophotometric estimation of the raltegravir potassium, an
integrase inhibitor antiretroviral agent was estimated by Ultra violet absorption
maxima method at λmax of 328 nm and UV area under curve method in the wave length
range of 323-333 nm. The Beer’s law obeyed in the concentration range of 3-55
μg/ml and correlation coefficients were found to be more than 0.996 for both
methods. The results of the analysis were 100.58±0.99 and 99.69±0.59 by
absorption maxima and area under curve method respectively. Both the methods were
validated as per ICH guidelines.

2. Angew Chem Int Ed Engl. 2008;47(22):4134-6. doi: 10.1002/anie.200703681.

A polar radical pair pathway to assemble the pyrimidinone core of the HIV
integrase inhibitor raltegravir potassium.

Pye PJ(1), Zhong YL, Jones GO, Reamer RA, Houk KN, Askin D.

Author information:
(1)Department of Process Research, Merck Research Laboratories, Rahway, NJ 07065,
USA.